| Project/Area Number |
20591013
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Kawasaki Medical School |
|---|
Principal Investigator |
OHSAWA Yutaka Kawasaki Medical School, 医学部, 講師 (80246511)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUNADA Yoshihide 川崎医科大学, 医学部, 教授 (00240713)
MURAKAMI Tatsufumi 川崎医科大学, 医学部, 准教授 (30330591)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2008: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | 神経分子病態学 / 筋ジストロフィー / 再生医療 / シグナル伝達 / 発生・分化 / 神経科学 |
|---|
| Research Abstract |
Inhibitor targeting the TGF-β type I receptor kinase, recently developed for cancer, reverses impaired myoblast differentiation caused by myostatin, activin, and TGF-β1. Inhibitor ameliorated muscular atrophy in a caveolin-3-deficient muscular dystrophy model with decrease of p21, a target gene of the TGF-β, and with increase of satellite cells. Inhibitor thus could be a rational drug for muscular atrophy.
|
